Biohaven inks up to $795M global Kv7 epilepsy platform deal with SK Bio

 

Biohaven inks up to $795M global Kv7 epilepsy platform deal with SK Biopharmaceuticals, receives $350M upfront

• SK Biopharmaceuticals receives exclusive worldwide rights to Biohaven's Kv7 ion channel platform and lead drug opakalim.
• Deal totals up to $795 million, including tiered royalties on future sales across the epilepsy franchise.
• Other payments include $50 million in 2027 and up to $150 million in milestone payments.
• SK Biopharmaceuticals assumes up to $245 million in development and commercialization obligations under the Kv7 collaboration.
• Transaction brings $400M near-term non-dilutive cash to Biohaven, spanning $350 million upfront plus $50 million payable in 2027.

https://finviz.com/stock?t=BHVN&p=d